JP4796967B2 - アルツハイマー病のためのバイオマーカー - Google Patents

アルツハイマー病のためのバイオマーカー Download PDF

Info

Publication number
JP4796967B2
JP4796967B2 JP2006538558A JP2006538558A JP4796967B2 JP 4796967 B2 JP4796967 B2 JP 4796967B2 JP 2006538558 A JP2006538558 A JP 2006538558A JP 2006538558 A JP2006538558 A JP 2006538558A JP 4796967 B2 JP4796967 B2 JP 4796967B2
Authority
JP
Japan
Prior art keywords
biomarker
alzheimer
cystatin
disease
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006538558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007524847A (ja
JP2007524847A5 (https=
Inventor
ヒュー アラン デイビス，
ジェイムス マグァイア，
アンジャ フヴィッド シモンセン，
カイ ブレンナウ，
ヴラディミール ポドスト，
Original Assignee
ヴァーミリオン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァーミリオン インコーポレイテッド filed Critical ヴァーミリオン インコーポレイテッド
Publication of JP2007524847A publication Critical patent/JP2007524847A/ja
Publication of JP2007524847A5 publication Critical patent/JP2007524847A5/ja
Application granted granted Critical
Publication of JP4796967B2 publication Critical patent/JP4796967B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2006538558A 2003-11-07 2004-11-06 アルツハイマー病のためのバイオマーカー Expired - Fee Related JP4796967B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US51836003P 2003-11-07 2003-11-07
US60/518,360 2003-11-07
US52675303P 2003-12-02 2003-12-02
US60/526,753 2003-12-02
US54642304P 2004-02-19 2004-02-19
US60/546,423 2004-02-19
US54725004P 2004-02-23 2004-02-23
US60/547,250 2004-02-23
US55889604P 2004-04-02 2004-04-02
US60/558,896 2004-04-02
US57261704P 2004-05-18 2004-05-18
US60/572,617 2004-05-18
US58650304P 2004-07-08 2004-07-08
US60/586,503 2004-07-08
PCT/US2004/037994 WO2005047484A2 (en) 2003-11-07 2004-11-06 Biomarkers for alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011012368A Division JP5479379B2 (ja) 2003-11-07 2011-01-24 アルツハイマー病のためのバイオマーカー

Publications (3)

Publication Number Publication Date
JP2007524847A JP2007524847A (ja) 2007-08-30
JP2007524847A5 JP2007524847A5 (https=) 2011-03-10
JP4796967B2 true JP4796967B2 (ja) 2011-10-19

Family

ID=34596275

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006538558A Expired - Fee Related JP4796967B2 (ja) 2003-11-07 2004-11-06 アルツハイマー病のためのバイオマーカー
JP2011012368A Expired - Fee Related JP5479379B2 (ja) 2003-11-07 2011-01-24 アルツハイマー病のためのバイオマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011012368A Expired - Fee Related JP5479379B2 (ja) 2003-11-07 2011-01-24 アルツハイマー病のためのバイオマーカー

Country Status (4)

Country Link
US (2) US7794948B2 (https=)
EP (3) EP2369347A1 (https=)
JP (2) JP4796967B2 (https=)
WO (1) WO2005047484A2 (https=)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7707134B2 (en) * 2005-01-14 2010-04-27 Siemens Medical Solutions Usa, Inc. System and method for molecular diagnosis of depression based on boosting classification
FR2882171A1 (fr) * 2005-02-14 2006-08-18 France Telecom Procede et dispositif de generation d'un arbre de classification permettant d'unifier les approches supervisees et non supervisees, produit programme d'ordinateur et moyen de stockage correspondants
WO2006106115A2 (de) * 2005-04-06 2006-10-12 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnose von alzheimer
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
AU2006259482A1 (en) * 2005-06-14 2006-12-28 Albert Einstein College Of Medicine Of Yeshiva University Effect of BRI proteins on abeta production
EP1907838B1 (en) * 2005-06-16 2011-06-01 Vermillion, Inc. Fragment of neurosecretory protein vgf as a biomarker for alzheimer's disease
WO2007012052A1 (en) * 2005-07-20 2007-01-25 Medical College Of Georgia Research Institute Use of protein profiles in disease diagnosis and treatment
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
WO2007105442A1 (ja) * 2006-02-22 2007-09-20 Kyowa Hakko Kogyo Co., Ltd. 摂食障害または摂水障害の治療薬
KR20080104350A (ko) 2006-02-28 2008-12-02 페노미넘 디스커버리스 인코포레이티드 치매 및 다른 신경 장애의 진단을 위한 방법
EP1996949A4 (en) 2006-03-11 2010-01-20 Univ Leland Stanford Junior BETA-2 MICROGLOBULIN AS A BIOMARKER FOR PERIPHERAL ARTERY DISEASE
WO2007136614A2 (en) * 2006-05-19 2007-11-29 Merck & Co., Inc. Assays and methods for the diagnosis and progression of alzheimer's disease using a multi-analyte marker panel
WO2007139777A2 (en) * 2006-05-26 2007-12-06 Merck & Co., Inc. Methods for the diagnosis and prognosis of alzheimer's disease using csf protein profiling
US7851172B2 (en) * 2006-07-25 2010-12-14 University Of Kentucky Research Foundation Biomarkers of mild cognitive impairment and alzheimer's disease
EP2076172A4 (en) * 2006-10-27 2012-03-21 Aretais Inc USE OF COHERENT RAMAN PROCEDURES FOR MEDICAL DIAGNOSTIC AND THERAPEUTIC PURPOSES AND CALIBRATION METHOD THEREFOR
DE102006056337A1 (de) * 2006-11-29 2008-06-05 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
GB0701626D0 (en) * 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
EP2620147B1 (en) 2007-02-08 2020-06-03 Med-Life Discoveries LP Compounds for lowering cholesterol
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
JP2010537200A (ja) 2007-08-21 2010-12-02 ワシントン ユニバーシティー 改善されたアルツハイマー診断法
WO2009114945A1 (en) 2008-03-21 2009-09-24 Neuman Manuela G Methods and kits for the differential diagnosis of alzheimer's disease versus frontotemporal dementia, and for the diagnosis of frontotemporal dementia, comprising fas-l and ckl 18 as biomarkers
US20140342381A1 (en) * 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
ES2665245T3 (es) 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Proceso de detección de biomarcador y ensayo de estado neurológico
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
EP2344881A4 (en) * 2008-09-26 2012-03-07 Univ Melbourne BIOMARKER FOR MORBUS ALZHEIMER
GB0818650D0 (en) 2008-10-10 2008-11-19 Uni I Oslo Methods
NZ628281A (en) * 2008-12-09 2016-05-27 Stephanie Fryar Williams Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
CN102300582A (zh) 2009-01-30 2011-12-28 阿尔法贝塔公司 用于治疗阿尔茨海默病的化合物和方法
WO2011005893A2 (en) * 2009-07-07 2011-01-13 Abbott Laboratories Biomarkers and methods for detecting alzheimer's disease
US9493834B2 (en) 2009-07-29 2016-11-15 Pharnext Method for detecting a panel of biomarkers
US20110097747A1 (en) * 2009-10-26 2011-04-28 Kevin Jones Monoclonal antibody binds antigen associated with human tumors
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
WO2012037232A2 (en) * 2010-09-16 2012-03-22 University Of Miami Compositions, methods and kits for detecting and treating alzheimer's disease
JP6012923B2 (ja) * 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
WO2012138284A1 (en) * 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
WO2013010170A1 (en) * 2011-07-14 2013-01-17 Lovell Mark A Process for detection of alzheimer's disease from a serum sample
CA2877975C (en) 2012-04-13 2021-09-21 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
US9678086B2 (en) 2012-09-10 2017-06-13 The Johns Hopkins University Diagnostic assay for Alzheimer's disease
US20140271463A1 (en) * 2013-03-12 2014-09-18 Stichting Vu-Vumc Bri2 as a novel biomarker for alzheimer's disease
WO2014144663A1 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014183023A1 (en) 2013-05-09 2014-11-13 Trustees Of Boston University Using plexin-a4 as a biomarker and therapeutic target for alzheimer's disease
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
JP2017505756A (ja) 2013-12-13 2017-02-23 ザ ジェネラル ホスピタル コーポレイション 可溶性高分子量（ｈｍｗ）タウ種およびその用途
WO2015152724A2 (en) 2014-04-02 2015-10-08 Stichting Vu-Vumc Biomarkers for the detection of frontotemporal dementia
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
GB201504432D0 (en) * 2015-03-17 2015-04-29 Electrophoretics Ltd Materials and methods for diagnosis and treatment of alzheimers disease
WO2017193115A1 (en) * 2016-05-06 2017-11-09 Nanosomix, Inc. Synaptic protein biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders
US10832089B2 (en) * 2016-05-11 2020-11-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for determining the temporal progression of a biological phenomenon and associated methods and devices
WO2018030252A1 (ja) * 2016-08-09 2018-02-15 大塚製薬株式会社 尿バイオマーカーを用いたアルツハイマー病の診断補助方法
JP6702836B2 (ja) * 2016-09-28 2020-06-03 ハルメク・ベンチャーズ株式会社 認知症判定得点算出装置及びそのプログラム
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
ES2600386B8 (es) * 2016-11-16 2017-08-04 Grifols Worldwide Operations Limited Método de diagnóstico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo
JP6359159B2 (ja) * 2017-07-25 2018-07-18 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
EP3740761A4 (en) * 2018-01-18 2021-10-20 University of North Texas Health Science Center at Fort Worth ACCOMPANYING DIAGNOSTICS FOR NSAIDS AND DONEPEZIL FOR THE TREATMENT OF SPECIFIC SUBPOPULATIONS OF PATIENTS WITH ALZHEIMER'S MORBUS
US11231401B2 (en) 2018-03-16 2022-01-25 Quest Diagnostics Investments Llc Methods for detecting chromogranin a by mass spectrometry
EP3765065A2 (en) * 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
KR20210035825A (ko) * 2018-07-19 2021-04-01 제넨테크, 인크. 마커 분자를 기반으로 아밀로이드-양성 치매를 갖거나 발생 위험성이 있는 개체를 식별하는 방법 및 관련 용도
WO2020069621A1 (en) * 2018-10-04 2020-04-09 University Of Manitoba Novel biomarker for alzheimer's disease in human
US11621087B2 (en) 2019-09-24 2023-04-04 International Business Machines Corporation Machine learning for amyloid and tau pathology prediction
US11657189B2 (en) 2020-03-30 2023-05-23 Kyndryl, Inc. Object loss prevention using cognitive computing
JP7109499B2 (ja) * 2020-05-07 2022-07-29 一般社団法人脳と心の健康科学研究所 認知症判定得点算出装置及びそのプログラム
JPWO2022070798A1 (https=) * 2020-09-29 2022-04-07
US20240077501A1 (en) * 2020-12-28 2024-03-07 Mcbi Inc. Judgment supporting information generating method, judgment supporting information generating system, and information processing device
CN115078570B (zh) * 2022-05-30 2024-05-28 郑州大学第一附属医院 Tau蛋白639位硫氰酸氨基酸修饰在快速质谱法检测阿尔茨海默症中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
ATE242485T1 (de) 1993-05-28 2003-06-15 Baylor College Medicine Verfahren und massenspektrometer zur desorption und ionisierung von analyten
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
AU3463699A (en) 1998-04-03 1999-10-25 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
WO2000025138A2 (en) * 1998-10-23 2000-05-04 Roger Nitsch Methods of diagnosing or prognosing alzheimer's disease
WO2000056934A1 (en) 1999-03-24 2000-09-28 Packard Bioscience Company Continuous porous matrix arrays
AU774336B2 (en) 1999-04-27 2004-06-24 Ciphergen Biosystems, Inc. Probes for a gas phase ion spectrometer
EP1181705A2 (en) 1999-04-29 2002-02-27 Ciphergen Biosystems, Inc. Sample holder with hydrophobic coating for gas phase mass spectrometers
JP5064625B2 (ja) 1999-10-27 2012-10-31 バイオウルフ テクノロジーズ エルエルスィー パターンを同定するための方法及び機械
WO2002002824A1 (en) 2000-07-03 2002-01-10 University Of South Florida Methods and assays for diagnosing alzheimer's disease
EP1386275A2 (en) 2000-07-18 2004-02-04 Correlogic Systems, Inc. A process for discriminating between biological states based on hidden patterns from biological data
EP1337845B1 (en) 2000-11-16 2012-01-04 Bio-Rad Laboratories, Inc. Method for analyzing mass spectra
CA2446666A1 (en) * 2001-05-09 2002-11-14 Biovision Ag Method for detecting progredient chronic dementia, and associated peptides and detection reagents
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US7541003B2 (en) 2001-07-17 2009-06-02 Bio-Rad Laboratories, Inc. Latex based adsorbent chip
JPWO2003027151A1 (ja) * 2001-09-25 2005-01-06 株式会社 免疫生物研究所 組換え抗オステオポンチン抗体およびその用途
US7842498B2 (en) 2001-11-08 2010-11-30 Bio-Rad Laboratories, Inc. Hydrophobic surface chip
US20030100016A1 (en) 2001-11-23 2003-05-29 George Jackowski Complement C3 precursor biopolymer markers predictive of Alzheimers disease
WO2003064594A2 (en) 2002-01-25 2003-08-07 Ciphergen Biosystems, Inc. Monomers and polymers having energy absorbing moieties of use in desorption/ionization of analytes
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
AU2003253014A1 (en) * 2002-06-21 2004-01-06 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
PT1535076E (pt) * 2002-08-23 2008-11-03 Bayer Healthcare Ag Marcadores biológicos para diagnóstico da doença de alzheimer
US7632686B2 (en) * 2002-10-03 2009-12-15 Anderson Forschung Group High sensitivity quantitation of peptides by mass spectrometry
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية

Also Published As

Publication number Publication date
EP2369348A1 (en) 2011-09-28
EP1694816A4 (en) 2008-08-20
US20050244890A1 (en) 2005-11-03
JP2007524847A (ja) 2007-08-30
EP2369347A1 (en) 2011-09-28
WO2005047484A3 (en) 2007-06-07
JP2011085601A (ja) 2011-04-28
US20110129920A1 (en) 2011-06-02
US7794948B2 (en) 2010-09-14
JP5479379B2 (ja) 2014-04-23
EP1694816A2 (en) 2006-08-30
WO2005047484A2 (en) 2005-05-26
EP1694816B1 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
JP4796967B2 (ja) アルツハイマー病のためのバイオマーカー
JP2007524847A5 (https=)
Davidsson et al. The use of proteomics in biomarker discovery in neurodegenerative diseases
US20110313681A1 (en) Biomarkers for peripheral artery disease
KR20070043868A (ko) 암에 대한 혈소판 바이오마커
US20120172356A1 (en) Serum biomarkers for chagas disease
US7993868B2 (en) Saposin D and FAM3C are biomarkers for alzheimer's disease
US20130073308A1 (en) Methods of Detecting a Fragment of Neurosecretory Protein VGF for Diagnosing Alzheimer's Disease
EP1907838B1 (en) Fragment of neurosecretory protein vgf as a biomarker for alzheimer's disease
HK1110388B (en) Fragment of neurosecretory protein vgf as a biomarker for alzheimer's disease
Carrette et al. Proteomic Applications for Molecular Assessment of Alzheimer's Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101020

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101027

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110704

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110801

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140805

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees